The issues of diagnosis, clinical course, the results of surgical treatment, immunotherapy and combined methods of treatment of patients with metastatic skin melanoma are considered. An attempt has been made to personalize the therapy. Received a complete response to treatment, improving the quality of life while maintaining robustness in a young patient. Methods. Patient B., 30 years old, who was diagnosed with melanoma of the skin of the back in GBUKKOD№1, was operated on in the surgery department of tumors of the skin and soft tissues. After identifying the progression of the disease, the patient was operated on with subsequent adjuvant immunotherapy and radiation therapy. After the progression of the disease was detected, the patient was prescribed a combination of targeted therapy with a full response. When a sustained full response was obtained, the patient was transferred to treatment with PD-1 inhibitors, against the background of which the progression of the disease was revealed, which required a return to the combination targeted therapy, as a result of which a full response was obtained again. Results. Personalized therapy was performed on a patient with progressive MK. The resulting increase in overall duration and quality of life. A full response to the combined targeted therapy with vemurafenib and cobimetinib was obtained twice after surgery, radiation therapy, immunotherapy (interferon-α) and treatment with control point inhibitors (nivolumab).

Full Text

Restricted Access

About the authors

Sergei A. Yargunin

Krasnodar cancer center #1

MD, PhD, the Head of the Department of Surgery for Skin of the Clinical Oncology Dispensary No.1, 350040, Krasnodar, Russian Federation 350040, Krasnodar, Russian Federation

A. F Lazarev

Altay State Medical University

656038, Barnaul, Russian Federation


  1. Демидов Л.В., Утяшев И.А., Харкевич Г.Ю. Роль вемурафениба в лечении диссеминированной меланомы кожи. Современная онкология. 2013; 2: 58-61.
  2. Орлова К.В., Харкевич Г.Ю., Демидов Л.В. Молекулярно-генетическая гетерогенность меланомы кожи и ее значение для разработки индивидуальных подходов к лечению. Фарматека. 2014; 17:18-24.
  3. Fava P., Astrua C., Sanlorenzo M., Ribero S., Brizio M., Filippi A.R. et al. Treatment of metastatic melanoma: a multidisciplinary approach. G. Ital. Dermatol. Venereol. 2017; 152 (3): 241-61. doi: 10.23736/S0392-0488.17.05633-4. Epub 2017 Mar 14. Review. PMID: 28290625.
  4. Ascierto P.A., Puzanov I., Agarwala S.S., Bifulco C., Botti G., Caracò C. et al. Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). J. Transl. Med. 2018; 16: 207. Published online 2018 Jul 21. doi: 10.1186/s12967-018-1568-6. PMCID: PMC6054754.
  5. Testori A., Ribero S., Bataille V. Diagnosis and treatment of in-transit melanoma metastases. Eur. J. Surg. Oncol. 2017; 43 (3): 544-60. doi: 10.1016/j.ejso.2016.10.005. Epub 2016 Oct 27. Review. PMID: 27923593.
  6. Miller A.J., Mihm M.C., Jr. Melanoma. N. Engl. J. Med. 2006; 355 (1): 51-65. PMID: 16822996.
  7. Fecher L.A., Cummings S.D., Keefe M.J., Alani R.M. Toward a molecular classification of melanoma. J. Clin. Oncol. 2007; 25 (12): 1606-0. PMID: 17443002. doi: 10.1200/JCO.2006.06.0442.
  8. Ko J.M., Fisher D.E. A new era: melanoma genetics and therapeutics. J. Pathol. 2011; 223: 241-50. doi: 10.1002/path.2804. Epub 2010 Oct 28. Review. PMID: 21125678.
  9. Vidwans S.J., Flaherty K.T., Fisher D.E., Tenenbaum J.M., Travers M.D., Shrager J.A. Мelanoma molecular disease model. PLoS One. 2011; 6 (3): e18257. PMID: 21479172. PMCID: PMC3068163. doi: 10.1371/journal.pone.0018257.
  10. Stinchcombe T.E., Socinski M.A., Walko C.M., O’Neil B.H., Collichio F.A., Ivanova A. et al. Phase 1 and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors. Cancer Chemother. Pharmacol. 2007; 60 (5): 759-66. Epub 2007 Feb 7. PMID: 17285317.
  11. Hersh E.M., O’Day S.J., Ribas A., Samlowski W.E., Gordon M.S., Shechter D.E. et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naïve patients with metastatic melanoma. Cancer. 2010; 116 (1): 155-63. doi: 10.1002/cncr.24720. PMID: 19877111.
  12. Kottschade L.A., Suman V.J., Amatruda T.3rd, McWilliams R.R., Mattar B.I., Nikcevich D.A. et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma. Cancer. 2011; 117 (8): 1704-10. doi: 10.1002/cncr.25659. Epub 2010 Nov 8. PMID: 21472717.
  13. Eggermont A.M., Chiarion-Sileni V., Grob J.J., Dummer R., Wolchok J.D., Schmidt H. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015; 16(5): 522-30. doi: 10.1016/S1470-2045(15)70122-1. Epub 2015 Mar 31. Erratum in: Lancet Oncol. 2015 Jun; 16(6):e262. Lancet Oncol. 2016 Jun; 17 (6):e223. PMID: 25840693.
  14. Строяковский Д.Л., Абрамов М.Е., Демидов Л.В., Новик А.В., Орлова К.В., Проценко С.А. и др. Практические рекомендации по лекарственному лечению меланомы кожи. Практические рекомендации по лекарственному лечению злокачествененых опухолей. 2017; 190-202. doi: 10.18027/2224-5057-2017-7-3s2-190-202.
  15. Fedorenko I.V., Abel E.V., Koomen J.M., Fang B., Wood E.R., Chen Y.A. et al. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene. 2015; doi: 10.1038/onc.2015.188. [Epub ahead of print]. PMID: 26 52.
  16. Grob J.J., Amonkar M.M., Karaszewska B., Schachter J., Dummer R., Mackiewicz A. et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, op Lancet Oncol. 2015; 16: 1389-98. PMID: 26433819. doi: 10.1016/S1470-2045(15)00087-X.
  17. Ugurel S., Röhmel J., Ascierto P.A., Flaherty K.T., Grob J.J., Hauschild A. et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur. J. Cancer. 2017; 83:247-257. doi: 10.1016/j.ejca.2017.06.028. Epub 2017 Aug 23. Review. PMID: 28756137. doi: 10.1016/j.ejca.2017.06.028. Epub 2017 Aug 23. Review. PMID: 28756137.
  18. De Wolf K., Kruse V., Sundahl N., van Gele M., Chevolet I., Speeckaert R. et al. A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastaticmelanoma: evaluation of clinical and immunologic response. J. Transl. Med. 2017; 15 (1):21. doi: 10.1186/s12967-017-1123-x. PMID: 28137295.
  19. Christiansen S.A., Khan S., Gibney G.T. Targeted Therapies in Combination With Immune Therapies for the Treatment of MetastaticMelanoma. Cancer J. 2017; 23(1): 59-62. doi: 10.1097/PPO.0000000000000245. Review. PMID: 28114256.
  20. Marzagalli M., Casati L., Moretti R.M., Montagnani Marelli M., Limonta P. Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines. PLoS One. 2015; 10 (7): e0134396. doi: 10.1371/journal.pone.0134396. eCollection 2015. PMID: 26225426 [PubMed - in process]. PMCID: PMC4520550.
  21. DePeralta D.K., Zager J.S. Metastasectomy for Abdominal Visceral Oligometastatic Melanoma. JAMA Surg. 2017; 152 (7): 678. doi: 10.1001/jamasurg.2017.0460. PMID: 28384678 doi: 10.1001/jamasurg. 2017.0460.
  22. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006; 439 (7077): 682-7.



Abstract: 145

Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2018 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies